Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Trifork Labs company Dawn Health welcomes Cipio Partners to fuel the next phase of growth for AI-driven commercial and clinical companion applications Press releaseCopenhagen — February 10, 2026 —...
-
Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR)...
-
Le rilzabrutinib de Sanofi a été désigné comme thérapie innovante aux États-Unis et comme médicament orphelin au Japon pour le traitement de l’anémie hémolytique auto-immune à anticorps chauds Le...
-
The US and Japan granted breakthrough therapy/orphan status to rilzabrutinib for wAIHA, a rare blood disorder marked by the destruction of red blood cells
-
ICP-538 is the first VAV1 degrader approved to enter clinical trials in China and the second globally.
-
WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced...
-
VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad...
-
FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
-
Pluristyx and Solesis launch ready-to-use kit combining high-quality pluripotent cells and mRNA technology with proprietary transfection technology
-
GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million. Reference is made to the stock exchange announcement published on 27 January 2026...